Traditional Chinese medicine (TCM) has thousands of years of history and remains a valuable repository. Numerous TCM-derived natural compounds show anti-cancer activity by regulating ROS and mitochondrial function. However, patient responses vary significantly. Cancer cells exhibit substantial heterogeneity in baseline ROS, mitochondrial membrane potential, and antioxidant capacity. Mitochondrial ROS is a double-edged sword-low levels promote proliferation; high levels induce death-and this balance differs across tumors. This variability may determine sensitivity to ROS-modulating compounds, yet it has not been exploited for personalized therapy. Here, we propose a phenotype-driven strategy to match patients with suitable TCM compounds based on their ROS/mitochondrial profile. This pan-cancer approach has three phases. First, establish a ROS/mitochondrial phenotype database by profiling cancer cell lines and patient samples across multiple cancer types (lung, breast, colon, oral). Parameters include intracellular ROS, mitochondrial superoxide, ??m, and glutathione. Second, screen natural compounds from TCM formulas against each phenotype subgroup to identify sensitivity patterns. Third, validate the strategy in xenograft models and a small patient cohort. We hypothesize that high-ROS tumors are sensitive to pro-oxidant compounds pushing ROS beyond a lethal threshold, while low-ROS or high-antioxidant tumors respond better to compounds inhibiting antioxidant defenses or targeting mitochondria. The expected outcome is a "ROS/mitochondria phenotype-compound matching matrix" to guide personalized TCM prescriptions. This strategy shifts TCM from "one-size-fits-all" to precision medicine, using ROS/mitochondrial phenotyping as a simple biomarker applicable to multiple cancer types.